Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Markets & Finance

UBS Warburg Trims Albany Molecular Estimates


UBS Warburg lowered its earnings estimates on drug research firm Albany Molecular Research (AMRI) after the company bosted slightly lower than expected revenues. The company reported second quarter net income of $8.5 million versus $5.8 million on a 42% revenue rise.

Analyst Iris Francesconi said total revenues were slightly below expectations due to the lower than anticipated Allegra royalties. Otherwise, results were essentially in line with estimates, she says. She says positive results are currently overshadowed by potential near term phasing out of its contract with duPont, which currently contribute about 19% to contract revenues. Still, Francesconi doesn't regard this as a devastating event. She is maintaining a strong buy on the stock while cutting 2002 earnings per share estimate to $1.14 from $1.19.


LIMITED-TIME OFFER SUBSCRIBE NOW
 
blog comments powered by Disqus